Match!

Liraglutide in children and adolescents with type 2 diabetes

Published on Sep 12, 2019
· DOI :10.1530/EY.16.12.5
William V. Tamborlane89
Estimated H-index: 89
,
Margarita Barrientos-Pérez2
Estimated H-index: 2
+ 13 AuthorsEllipse Trial I1
Estimated H-index: 1
Abstract
  • References (0)
  • Citations (2)
📖 Papers frequently viewed together
1 Citations
2013
2 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References0
Newest
Cited By2
Newest
Source
#1Charlotte M. Mosterd (UvA: University of Amsterdam)
#2Petter Bjornstad (University of Colorado Denver)H-Index: 20
Last. Daniël H. van Raalte (UvA: University of Amsterdam)H-Index: 20
view all 3 authors...
Glucagon-like peptide (GLP)-1 receptor agonists are the cornerstone in the treatment of hyperglycemia in many people suffering from type 2 diabetes (T2D). These drugs have potent glucose-lowering actions and, additionally, lower body weight through satiety induction while reducing blood pressure and dyslipidemia. Partly through these actions, GLP-1 receptor agonism was shown to reduce cardiovascular disease (CVD) in people with T2D with previous CVD or at high-risk thereof. In these cardiovascul...
Source